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For the prevention of exacerbations bronchodilators 
and inhaled glucocorticoids are used in combination 
with long-acting β2-adrenomimetics (severe and very 
severe COPD).  Yearly influenza vaccination is highly 
recommended.
In conclusion, it should be noted that if the antibiotic 
therapy is chosen correctly for the individual, it reduces 
the duration of hospital stay and the costs associated with 
medical care.
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Abstract
The study involved 23 patients with decompensated liver cirrhosis and ascitic syndrome.  This trial was designed to determine the value of serum-
ascites and lymphatic albumin gradients.  We established diminution of the albumin ascites-lymphatic gradient in relationship with the evolution of the 
ascitic syndrome.  We introduce the notion of serum/ascites/lymphatic albumin gradient and its significance on parameters of the evolution of the ascitic 
syndrome.  It is required to validate the clinical application of the gradient in following studies.
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Изменения альбуминового градиента (асцит, плазма, лимфа)  
у декомпенсированных больных циррозом печени и асцитическим синдромом
В настоящую работу включены 23 больных с декомпенсированным циррозом печени и асцитическим синдромом.  Исследование было 
посвящено изучению и оценке альбуминового градиента (асцит, плазма, лимфа).  Установлено уменьшение альбуминового градиента асцит-
лимфа в соотношении с развитием асцитического синдрома.  Впервые предложена терминология альбуминового градиента (асцит, плазма, 
лимфа), однако его значение, как критерия развития асцитического синдрома, требует уточнения в дальнейших исследованиях.
Ключевые слова: асцитический синдром, градиент концентрации альбумина сыворотка-асцит.
Introduction
According to literature data, 4-5% of the global po-
pulation shows disturbances of liver functions, of which 
about 10-20% are caused by viral hepatitis, toxic hepatitis 
or ethanol alcohol, that within 10-20 years lead to the 
evolution of cirrhosis liver [1], which inevitably leads to 
a high rate of complications such as variceal hemorrhage 
either cirrhogenous hypersplenism with coagulopathy in 
progress or ascitic syndrome.  Thus, N. Fisher et al. notes 
that in Great Britain alone, during the years 1993-2000, 
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the mortality from complications of liver cirrhosis doubled 
from 6 x 105 in 1993 to 12.7 x 105 in 2000 [3].
In this context the problem of diagnosis, prophylaxis, and 
treatment of complications of cirrhotic portal hypertension 
is current and remains the focus of the medical community.
Ascitic syndrome, and especially in its advanced forms 
(with lack of response to diuretic therapy) is one of the most 
serious complications of liver cirrhosis, which according to 
different authors evolves in 50 percent of cases within 10 years 
of diagnosis of hepatic cirrhosis.  More than that, statistics of 
randomized trials denote a rate of mortality within the limits 
of 60-70% of cases of these patients in terms of 24-36 months 
from the onset of resistant and refractory ascites (called in 
some publications as intractable ascites) [3, 4], which in our 
view is debatable.
Besides a reduced quality of life, in cases of medically or 
surgically uncontrolled evolution of ascitic syndrome, patients 
are at high risk of appearance of hepato-renal failure, due to 
the fact that in general, hepato-renal failure has 5-year inci-
dence rate of 18-39% in cirrhotic patients primarily diagnosed, 
the prognosis being extremely poor [5-8], and as a “golden” 
therapeutic option only liver transplantation is being con-
sidered [9], which currently can not fully solve the problem 
because of the small number of organ donations.
Meanwhile, another major complication in advanced 
cirrhogenous ascites is ascites fluid infection.  The develop-
ment of spontaneous bacterial peritonitis by intestinal flora 
translocation and bacteremia in the lymph nodes in turn 
contributes to deterioration of liver and kidney functions [6].
Thus, future research on the assessment of prognostic 
factors triggering spontaneous bacterial ascites-peritonitis, 
without the need for sophisticated laboratory tests, is reaso-
nable and also useful to medical practitioners.
Over the past decades in order to differentiate and diagnose 
the etiology of ascites (portal hypertension, peritoneal carcinoma-
tosis, tuberculous peritonitis, secondary bacterial or neoplastic), 
using concepts of exudative vs transudative properties, we studied 
the total protein concentration in ascitic fluid and serum.  Con-
ventionally, it was established that neoplastic ascites (“exudative 
theory”) have a characteristic protein index of > 25 g/l, while in 
portal hypertension (“transsudative conception”) the value of 
protein concentration is < 25 g/l.
Later, a new biochemical criterion was proposed and 
namely - assessing the difference in serum albumin concentra-
tion and ascitic fluid, or the so-called gradient album serum/
ascites (GASA), which proved to be a higher sensitivity com-
pared to determination of the total concentration of proteins 
in ascitic and serum fluid [12].  Simultaneously, investigations 
indicate that the value (GASA) > 1.1 g/dl denotes ascitic syn-
drome in portal hypertension with an accuracy of 97% [12] 
while the value of the named gradient below 1.1 g/dl, is cha-
racteristic to ”non-portal hypertension etiology” [13, 14, 15].
Also, no research literature exists regarding the role of 
the serum-ascites-lymph albumin gradient in evaluating the 
severity of cirrhotic syndrome.
Aim of the study - the analysis of albumin concentration, 
serum and lymph in decompensated cirrhotic patient with 
ascitic syndrome, the serum-ascitic albumin gradient analysis, 
lymph and its variations depending on the stage of ascites and 
hepatic functional reserve.
Material and methods
This study included a prospective analysis of changes in 
the serum-ascitic-lymphatic albumin gradient in 23 cirrhotic 
patients with advanced cirrhosis with ascites (13 - resistant, 
10 - refractory), surgically treated in the Surgery Clinic “Sfinta 
Treime” (“Holy Trinity”) in the period 2008 - 2010.
The study group included 11 men and 12 women ran-
ging in age limits of 45-58 years, etiology of liver cirrhosis 
was caused by viral hepatitis (HBV, HBV + HBV-HDV and 
HCV in 7, 6 and 10 cases respectively, confirmed by immu-
noserological investigations.  Average Child-Pugh score was 
10.4 ± 1.28 points.  Patients were separated into previously 
described stages of ascites syndrome in accordance to criteria 
for classification of Ascites International Club (Internatio-
nal Club of Ascites).  We mention the fact that the patients 
with activation of cirrhotic process were not included in the 
research group.  Additionally, perfusion conservative treat-
ment with administration of albumin, plasma, etc. in terms 
of the previous three months was considered as a criterion of 
exclusion from the study.
The surgical treatment included the cervical decompressi-
on of the thoracic lymph duct, which in 6 cases was associated 
with paracentesis decompression, performed in patients with 
tense ascites and cardiopulmonary disturbances.
In order to standardize the research the biological sub-
strate was investigated (serum, lymph and ascitic fluid) and 
was collected only intraoperative under sterile conditions, 
being collected 5.0 ml of serum and ascitic fluid obtained by 
paracentesis.  Intraoperatively the thoracic lymph duct was 
punctured with SECALON catheter (Becton Dickinson Cri-
tical Care Systems, USA) and the lymph fluid was collected.
The collected biological fluids were subjected to laboratory 
research with clinical and general bacteriological proteino-
gram assessment, and especially the measurement of albumin 
concentration.  A general characteristic of patients included 
in the study is summarized in tab. 1.
Table 1
Structure of the study group (n = 23)
Ascites Men / Women Average age Child Average Score
Resistant   7/6 42.6 ± 2.3   9.8 ± 0.35
Refractory   7/3 48.1 ± 2.5 10.6 ± 0.45
Total 14/9 45.8 ± 2.1 10.2 ± 0.15
Obtained results
The results of research conducted on a group of 23 pati-
ents with hepatic decompensate cirrhosis were estimated and 
analyzed according to the severity of the ascitic syndrome 
(resistant / refractory).  It was found that the albumin concen-
tration in serum, lymph and ascites did not differ statistically 
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or significantly in those groups.  Serum albumin concentra-
tion in resistant as compared to refractory ascites was 2.65 ± 
0.78 (gm/dl) and 2.45 ± 0.89 respectively. The corresponding 
lymph and ascites albumin concentrations in resistant ascites 
were 2.15 ± 0.88 and 1.01 ± 0.98 respectively, while in refractory 
ascites they were 1.87 ± 0.76 and 0.93 ± 0.66, p > 0.05 (tab. 2).
Table 2
Profile of serum albumin, ascites and lymph to patients 
included in the study group (n = 23)
Index Resistant ascites 
Refractory 
ascites p
Serum albumin concentration 
(gm/dl) 2.65 ± 0.78 2.45 ± 0.89 > 0.05
Lymph albumin concentration 
(gm/dl) 2.15 ± 0.88 1.87 ± 0.76 > 0.05
Ascites albumin concentration 
(gm/dl) 1.01 ± 0.98 0.93 ± 0.66 > 0.05
We conclude that in this study the quantitative assessment 
of albumin concentration in serum, ascitic fluid and lymph 
was not predictive of the development of complicated cir-
rhogenous ascites in patients with decompensated cirrhosis.
Simultaneously, in both study groups, the albumin gra-
dient of serum-ascites included higher values of 1.1 (gm/dl) 
in 100% cases confirming the value of this parameter as a 
characteristic sign of portal hypertension, justifying in this 
sense, the “transsudative “ hypothesis of differential diagnosis 
of ascites [12, 17, 20].
The analysis of albumin gradients in resistant and re-
fractory ascites was, respectively 0.48 ± 0.09 and 0.51 ± 0.11 
gm/dl for serum-lymph gradient, and 1.05 ± 0.20 and 0.89 ± 
0.07, for lymph-ascites gradient.  Also we found, that ascites-
lymph albumin gradient decreases during the evolution of 
lymph-ascitic syndrome, with a tendency to decrease with the 
progression of advanced forms, although these results were 
non-significant (p > 0.05)
Table 3
Changes in albumin gradient in the study group (n = 23)
Index Resistant ascites 
Refractory 
ascites p
Albumin gradient
Ser - ascites (gm/dl) 1.56 ± 0.64 1.49 ± 0.75 > 0.05
Albumin gradient
Ser - Lymph (gm/dl) 0.48 ± 0.09 0.51 ± 0.11 > 0.05
Albumin gradient
Lymph-ascites (gm/dl) 1.05 ± 0.20 0.89 ± 0.07 > 0.05
Albumin gradient
Ser/ascites/Lymph * -0.40 ± 0.05 -0.90 ± 0.10 < 0.01
* Negative values of the gradient
On further analysis of our date, we found that the 
albumin gradient in ser/ascites/lymph proved to be more 
sensitive in differentiating resistant vs refractory ascites 
as compared to the analysis of albumin concentration in 
each of the biological fluids analyzed separately or in pairs. 
This can be explained by the multiplicity and complexity 
of peritoneal absorption mechanisms, the phenomenon 
of “washing” of albumin in ascitic fluid, described by JH 
Henriksen [16].  In this study we noted a statistically signi-
ficant difference in the groups investigated for this index, 
namely a serum/ascites/lymph albumin gradient of - 0.40 
± 0.05 in the resistant ascites group vs - 0.90 ± 0.10 in the 
refractory ascites group (p < 0.01).
Table 3 summarizes research data of albumin gradients.
Discussions
The evolution of ascitic syndrome with advancing compli-
cations represents a difficult clinical problem, both medically 
and surgically [17].  Also, many randomized trials have evalua-
ted various laboratory parameters of ascitic fluid, which would 
allow the differentiation of etiology, such as: proteinogram, 
cytology, albumin gradient serum/ascites, measurement of 
lactate hydrogenase concentration, amylase, adenosine dea-
minase, glucose, fibronectin level [18, 19].
It is known that, in peritoneal fluid of healthy individuals 
the physiological concentration of proteins exceeds the va-
lue of 4 g/dl, while in ascites, serum protein concentrations 
decrease to below 2.5 g/dl.  This traditional concept is also 
debatable because patients with ascites are usually treated 
conservatively with diuretics and infusions of plasma or al-
bumin, leading to increased protein concentration in ascitic 
fluid and thus decreasing the sensitivity of a low serum protein 
measurement [20].
Therefore a new criterion-gradient of album serum/
ascites was proposed, which proved to have a higher sen-
sitivity compared to determination of total protein con-
centration in ascitic fluid and serum [12].  This gradient is 
based not on a simple assessment of albumin concentration 
in the above-mentioned fluids, but serves as a reflection of 
portal pressure, being derived on the basis of oncotic and 
hydrostatic balance.
Thus, the research shows a direct connection between 
the serum/ascites albumin gradient and the degree of portal 
hypertension.  This ratio is clearly superior compared to 
the overall concentration of proteins in serum and ascites 
[22, 23].  More than that, some authors recorded a direct 
connection between the value of portal pressure gradient 
GASA, as well as its complications, gastro-esophageal 
varices and ascitic syndrome [24, 26].  However, in this 
study we were unable to confirm a significant serum-ascites 
albumin gradient difference between patients with resistant 
and refractory ascites.
Investigations of lymph fluid components were started in 
the 60s, with achievements in clinical and experimental studies 
by several of the well-known men of science who were also the 
founders of this field, A. Dumont, 1960, H. Mayerson, 1963, 
M. Orloff, 1966, C. Witte, 1968 [27-29].
Meanwhile, in spite of a long period of time, available 
literature does not show any scientific works towards protein 
variations, especially albumin in serum, ascites and lymph 
appreciation of these gradients.  This can be explained by 
deficiencies in obtaining lymph from lymph central collector 
(thoracic duct), as well as a relatively small number of men of 
science specialized in the field.
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Conclusions
Quantitative assessment of albumin concentration in 
serum, ascitic fluid and lymph is not an index revealing the 
prognosis in terms of evolution of ascites to patients with 
cirrhogenous decompensated cirrhosis.  This study found 
that serum-ascites albumin gradient does not reveal a signi-
ficant difference in the case of resistant and refractory ascites. 
Ascites albumin gradient decreases during the evolution of 
lymph and ascitic syndrome and has a tendency to decrease 
with the progression of advanced forms of ascitic syndrome. 
Implementation of the notion of serum-ascites-lymph albu-
min gradient and its significance as a criterion of evolution 
for ascitic syndrome requires further study and validation.
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Abstract
This research presents the experience of the Arterial Hypertension Department in the treatment of patients with essential hypertension and 
microalbuminuria.  The study focused on the analysis of clinical observation materials according to the protocol, established in a group of 100 patients, of 
whom 50 were treated with angiotensin II converting enzyme inhibitors Ramipril and 50 were treated with angiotensin II receptor antagonist Eprosartane. 
Both drugs have proven beneficial effect on renal function parameters, especially in microalbuminuria at all stages of control with a peak at the end of 
the follow-up period.  However, the treatment with AT1-receptor antagonist Eprosartan has proven to be superior to angiotensin II in converting enzyme 
inhibitor Ramipril.
Key words: arterial hypertension, microalbuminuria, angiotensin II converting enzyme inhibitors, angiotensin II receptor antagonist.
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